Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2024-05-13
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well nivolumab and brentuximab vedotin work in treating older
patients with untreated Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Biological therapies, such as brentuximab vedotin,
use substances made from living organisms that may stimulate or suppress the immune system in
different ways and stop cancer cells from growing. Nivolumab and brentuximab vedotin may work
better in treating older patients with untreated Hodgkin lymphoma.